Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.9, 2014-06, pp. : 1299-1313

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cognitive and Functional Influences of Vildagliptin, a DPP-4 Inhibitor, Added to Ongoing Metformin Therapy in Elderly with Type 2 Diabetes

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 13, Iss. 3, 2013-09 ,pp. : 256-263

Bentham Science Publishers

Access to resources Recommend Favorite

Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes

By Stein Stephanie A Lamos Elizabeth M Davis Stephen N

Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, Iss. 4, 2014-04 ,pp. : 599-608

Informa Healthcare

Access to resources Recommend Favorite

Vildagliptin in the treatment of type 2 diabetes mellitus

By Stamataros George Schneider Stephen H

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 12, 2011-08 ,pp. : 1967-1973

Informa Healthcare

Access to resources Recommend Favorite

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

By Guarino Elisa Nigi Laura Patti Aurora Fondelli Cecilia Dotta Francesco

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1377-1384

Informa Healthcare

Access to resources Recommend Favorite

Comparison of once-weekly with twice-daily exenatide in the treatment of type 2 diabetes (DURATION-1 trial)

By Raskin Philip Mohan Alok

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 13, 2010-09 ,pp. : 2269-2271

Informa Healthcare

Access to resources Recommend Favorite